289 related articles for article (PubMed ID: 26224203)
1. Drug-metabolism mechanism: Knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions.
Tolbert D; Bekersky I; Chu HM; Ette EI
J Clin Pharmacol; 2016 Mar; 56(3):365-74. PubMed ID: 26224203
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
3. Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy.
Russell GR; Phelps SJ; Shelton CM; Wheless JW
Ther Drug Monit; 2018 Aug; 40(4):452-462. PubMed ID: 29746397
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G
Epilepsia; 2020 Sep; 61(9):1854-1868. PubMed ID: 32918835
[TBL] [Abstract][Full Text] [Related]
5. An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics.
Tolbert D; Bekersky I; Chu HM; Ette EI
J Clin Pharmacol; 2016 Feb; 56(2):213-22. PubMed ID: 26139309
[TBL] [Abstract][Full Text] [Related]
6. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.
Saruwatari J; Ogusu N; Shimomasuda M; Nakashima H; Seo T; Tanikawa K; Tsuda Y; Nishimura M; Nagata R; Yasui-Furukori N; Kaneko S; Ishitsu T; Nakagawa K
Ther Drug Monit; 2014 Jun; 36(3):302-9. PubMed ID: 24345815
[TBL] [Abstract][Full Text] [Related]
7. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy.
Contin M; Riva R; Albani F; Baruzzi AA
Ther Drug Monit; 1999 Dec; 21(6):604-8. PubMed ID: 10604819
[TBL] [Abstract][Full Text] [Related]
8. Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy.
Yamamoto Y; Takahashi Y; Imai K; Takahashi M; Nakai M; Inoue Y; Kagawa Y
Eur J Clin Pharmacol; 2014 Oct; 70(10):1203-10. PubMed ID: 25048408
[TBL] [Abstract][Full Text] [Related]
9. A Thorough QT/QTc Study of Clobazam in Healthy Volunteers.
Tolbert D; Gordon J; Harris S; Walzer M; Bekersky I; Reid S
Clin Ther; 2017 Oct; 39(10):2073-2086. PubMed ID: 28958437
[TBL] [Abstract][Full Text] [Related]
10. A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam.
Tolbert D; Larsen F
J Clin Pharmacol; 2019 Jan; 59(1):7-19. PubMed ID: 30285275
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid.
Jullien V; Chhun S; Rey E; Dulac O; Tod M; Chiron C; Pons G
Clin Pharmacokinet; 2015 May; 54(5):527-36. PubMed ID: 25503589
[TBL] [Abstract][Full Text] [Related]
12. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.
de Leon J; Spina E; Diaz FJ
Ther Drug Monit; 2013 Feb; 35(1):30-47. PubMed ID: 23318278
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy.
Yamamoto Y; Takahashi Y; Imai K; Miyakawa K; Nishimura S; Kasai R; Ikeda H; Takayama R; Mogami Y; Yamaguchi T; Terada K; Matsuda K; Inoue Y; Kagawa Y
Ther Drug Monit; 2013 Jun; 35(3):305-12. PubMed ID: 23666564
[TBL] [Abstract][Full Text] [Related]
14. Interactions of clobazam with conventional antiepileptics in children.
Theis JG; Koren G; Daneman R; Sherwin AL; Menzano E; Cortez M; Hwang P
J Child Neurol; 1997 Apr; 12(3):208-13. PubMed ID: 9130097
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability.
Burns ML; Baftiu A; Opdal MS; Johannessen SI; Landmark CJ
Ther Drug Monit; 2016 Jun; 38(3):350-7. PubMed ID: 26751267
[TBL] [Abstract][Full Text] [Related]
16. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.
Kosaki K; Tamura K; Sato R; Samejima H; Tanigawara Y; Takahashi T
Brain Dev; 2004 Dec; 26(8):530-4. PubMed ID: 15533655
[TBL] [Abstract][Full Text] [Related]
17. Interaction between sulthiame and clobazam: sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19.
Yamamoto Y; Takahashi Y; Imai K; Mogami Y; Matsuda K; Nakai M; Kagawa Y; Inoue Y
Epilepsy Behav; 2014 May; 34():124-6. PubMed ID: 24742983
[TBL] [Abstract][Full Text] [Related]
18. Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures.
Klein P; Tolbert D; Gidal BE
Epilepsy Behav; 2019 Oct; 99():106459. PubMed ID: 31519475
[TBL] [Abstract][Full Text] [Related]
19. Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome.
Tolbert D; Chu HM; Ette EI
Epilepsy Res; 2019 Nov; 157():106182. PubMed ID: 31563030
[TBL] [Abstract][Full Text] [Related]
20. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
